Jiangsu Hengrui Medicine Co., Ltd. (HKG:1276)
82.05
+2.75 (3.47%)
At close: Aug 15, 2025, 4:00 PM HKT
Jiangsu Hengrui Medicine Revenue
Jiangsu Hengrui Medicine had revenue of 7.21B CNY in the quarter ending March 31, 2025, with 20.14% growth. This brings the company's revenue in the last twelve months to 29.19B, up 25.16% year-over-year. In the year 2024, Jiangsu Hengrui Medicine had annual revenue of 27.98B with 22.63% growth.
Revenue (ttm)
29.19B CNY
Revenue Growth
+25.16%
P/S Ratio
14.75
Revenue / Employee
1.44M CNY
Employees
20,238
Market Cap
461.51B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 27.98B | 5.16B | 22.63% |
Dec 31, 2023 | 22.82B | 1.54B | 7.26% |
Dec 31, 2022 | 21.28B | -4.63B | -17.87% |
Dec 31, 2021 | 25.91B | -1.83B | -6.59% |
Dec 31, 2020 | 27.73B | 4.45B | 19.09% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines | 35.81B |
Hansoh Pharmaceutical Group Company | 13.05B |
JD Health International | 61.89B |
Innovent Biologics | 10.03B |
Akeso | 2.26B |
Sino Biopharmaceutical | 30.72B |
WuXi Biologics | 19.87B |
CSPC Pharmaceutical Group | 28.99B |